Trial Profile
A Retrospective cohort study assessing the safety and efficacy of Tolvaptan and Conivaptan for the treatment of Hyponatremia in Neurocritically Ill Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Mar 2017
Price :
$35
*
At a glance
- Drugs Conivaptan (Primary) ; Tolvaptan (Primary)
- Indications Hyponatraemia
- Focus Therapeutic Use
- 28 Mar 2017 New trial record
- 12 Mar 2017 Results published in the Pharmacotherapy